Researchers finds Irish Lupus patients likely to benefit from new treatment

May 7, 2013

Researchers from the Royal College of Surgeons in Ireland (RCSI) have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus (SLE) could potentially benefit Irish patients who suffer from the condition.

SLE is an autoimmune disease whereby a person's immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage. SLE most often harms the skin, joints, blood vessels, kidneys and the nervous system. SLE is a rare condition in Ireland, affecting approximately 1,500 people. It can affect up to 10 times as many women as men. The research has identified Irish SLE patients that are susceptible to active disease and increased organ damage brought on by lupus as it progresses. This is due to the presence of high levels of a called Stimulator (BLyS) in the body. This messenger can cause the body's cells to produce antibodies that attack its own tissues, thus causing .

The effects of BLyS are specifically targeted by a new drug called Belimumab (Benlysta). It is the first drug to be approved by the European Medicines Agency to treat lupus in more than 50 years. The research will help doctors identify patients that are most likely to benefit from the drug as not all patients may respond to the treatment.

Professor Caroline Jefferies, Associate Professor in Molecular and Cellular Therapeutics (MCT), RCSI and principal investigator of the study, commented, 'Lupus is a very complex disease and one of the biggest challenges, currently, is identifying the patients who are most likely to benefit from as they are approved. Our research suggests that simply measuring BLyS levels in patients may identify those who will best respond to Belimumab, thus improving the long-term outcomes for these patients.'

This research was recently published in Rheumatology.

Belimumab is used to treat who don't respond to usual medication comprising of a combination of steroids and immunosuppressive anti-inflammatory drugs, both of which have side effects following long-term use.

Explore further: Research: Lupus drugs carry no significant cancer risk for patients

More information: McCarthy, E. et al. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology. doi:10.1093/rheumatology/ket120

Related Stories

Research: Lupus drugs carry no significant cancer risk for patients

January 24, 2013
People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). ...

Predictors of organ damage identified in patients with SLE

December 16, 2012
(HealthDay)—Patient age, hypertension, and corticosteroid use are the most important predictors of the cumulative organ damage that occurs in patients with systemic lupus erythematosus (SLE), according to research published ...

A nanogel-based treatment for lupus

March 1, 2013
Systemic lupus erythematosus (SLE) is disease in which the immune system mistakenly attacks healthy tissues, resulting in inflammation and tissue damage. Current treatments are focused on suppression of the immune system, ...

Belimumab deemed safe for long-term lupus treatment

June 19, 2012
(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

Recommended for you

Study shows prevalence of knee osteoarthritis has doubled since World War II

August 14, 2017
The average American today is twice as likely to be diagnosed with knee osteoarthritis than in the years before World War II, Harvard scientists say, but that increase can't be blamed on the reasons most might think.

Researchers find arthritis drug could treat blood cancer patients

August 3, 2017
Blood cancer sufferers could be treated with a simple arthritis drug, scientists at the University of Sheffield have discovered.

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.